Lupin stock jumps on US FDA approval updates in 2025

Market snapshot: shares climb on regulatory newsflow

Lupin Ltd shares moved higher in trade after multiple US regulatory updates kept the stock in focus. In one market update, the stock rose 1.38% to Rs 2,062, its highest level since May 19. The move came alongside news that the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Aurangabad facility, following a product-specific pre-approval inspection conducted in September.

Separately, Lupin reported progress on two key products for the US market, one in HIV treatment and another in nephrology. Together, these developments reinforced investor attention on Lupin’s US generics pipeline and manufacturing readiness.

Aurangabad facility: US FDA Establishment Inspection Report received

Lupin said it has received an EIR from the US FDA for its Aurangabad facility. The EIR follows a product-specific pre-approval inspection carried out in September, as per the market update.

For investors in Indian pharmaceutical companies, an EIR is closely watched because it indicates the inspection process has moved to a documented outcome. In regulated markets like the US, inspection outcomes influence product approvals, supply continuity, and confidence in manufacturing compliance.

Tentative approval: generic HIV treatment tablets

In another update, Lupin said it received tentative approval from the US FDA for its HIV treatment tablets. The company informed exchanges that it has secured tentative approval for its Abbreviated New Drug Application (ANDA) for bictegravir, emtricitabine, and tenofovir alafenamide tablets (50 mg/200 mg/25 mg).

Lupin said the product would be manufactured at its Nagpur facility in India. The company also stated the product is the generic equivalent of Biktarvy tablets (50 mg/200 mg/25 mg), marketed by Gilead Sciences Inc, and is indicated for treatment of HIV infection in adults and pediatric patients weighing at least 25 kg.

Tentative approval typically indicates the ANDA has met requirements but cannot be finally approved until certain conditions are met, such as exclusivity periods or patent-related timelines. Lupin’s disclosure focused on the status and manufacturing site, without providing a launch timeline in the update.

Tolvaptan: US FDA approval and first-to-file exclusivity

On April 24, 2025, Lupin announced it received US FDA approval for its ANDA for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. The company said the product is bioequivalent to Jynarque Tablets of Otsuka Pharmaceutical Company.

Lupin stated it holds exclusive first-to-file status for this product and is eligible for 180 days of generic drug exclusivity. The company said the product will be manufactured at its Nagpur facility in India and will be launched soon, without specifying an exact date.

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), according to the company’s release.

How the stock traded: key price levels and momentum

Price action across multiple sessions reflected the steady flow of US-facing updates. In one trading update, Lupin shares climbed as much as 2.1% to a day’s high of Rs 2,034.95 on the BSE, from a prior close of Rs 1,991.20. By 11:33 am, the stock was up 1.19% at Rs 2,014.90, giving the company a market capitalisation of Rs 92,031 crore. The stock was also noted to have gained in 12 of the last 15 trading sessions.

Another data point in the update highlighted that at current levels the stock was trading 13% above its 52-week low of Rs 1,774, and around 1.3% below its 52-week high of Rs 2,403.45.

For the May 13, 2025 session, Lupin shares rose 3.65% to Rs 2,114.30 on the NSE intraday. At 12:20 PM, the stock was at Rs 2,082.50, up 2.09% from a previous close of Rs 2,039.80. The NSE 52-week range was cited as Rs 2,402.90 to Rs 1,493.30.

Analyst and broker signals: price targets and estimates cited

The market update cited LSEG-compiled data showing Lupin was rated “buy” on average, with a median price target of Rs 2,265. It also noted the stock was down 12.5% year-to-date (YTD) at that point.

In a separate analyst commentary included with the coverage of Tolvaptan, analysts were cited as expecting a revenue opportunity of about USD 150 million to USD 200 million for FY26. The same commentary said gTolvaptan could contribute 25% plus to Lupin’s FY26 earnings, and that Access Capital revised FY26 EBITDA and profit outlook, factoring an 8% to 10% increase from previous estimates.

These figures were presented as external expectations rather than company guidance, and should be read in that context.

What it means for Lupin’s US generics strategy

The combination of manufacturing site references and regulatory outcomes points to the operational side of Lupin’s US strategy. The company repeatedly identified the Nagpur facility as the manufacturing site for both the HIV tablets and Tolvaptan, while the Aurangabad facility update addressed inspection documentation.

For Indian drugmakers, a strong cadence of US FDA actions can matter as much as product wins because approvals and inspections determine how quickly products can be supplied and scaled. The 180-day exclusivity period, when applicable, can also influence early market share dynamics for complex or high-value generics.

Key facts at a glance

Conclusion: steady US FDA updates keep Lupin in focus

Lupin’s recent stock moves have been closely tied to US FDA-related updates across plants and products, including an EIR for Aurangabad, tentative approval for a generic HIV combination tablet, and approval for Tolvaptan with first-to-file exclusivity. With manufacturing for key products linked to its Nagpur facility and a “launch soon” statement for Tolvaptan, the next catalyst investors will watch is execution, including the timing and scale of commercial rollout in the US.